BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
How comfort foods trigger pleasure in our brains- Mom finds out she has cancer after noticing something was off while breastfeeding
- ByHeart infant formula recall tied to botulism outbreak puts parents on edge
- Mexican Woman Accused of Assaulting Partner With Belt After He Refused Sex, Police Say
- Flu cases skyrocket in US. See cases, where people got sick.
- Ryan Gosling responds to Deidre Hall's invitation to visit the 'Days of Our Lives' set: 'This is a very enthusiastic yes'
- What's your #1 tone
- Inn The executives: A Remunerating Profession Decision for Energetic People
- Employers and staff feel effect of fuel price rise
